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Co-exposure to benzo[a]pyrene 
and ethanol induces a pathological 
progression of liver steatosis in vitro 
and in vivo
Simon Bucher1, Arnaud Tête2, Normand Podechard2, Marie Liamin2, Dounia Le Guillou1, 
Martine Chevanne2, Cédric Coulouarn1, Muhammad Imran2, Isabelle Gallais2,  
Morgane Fernier2, Quentin Hamdaoui1, Marie-Anne Robin1, Odile Sergent2,  
Bernard Fromenty1 & Dominique Lagadic-Gossmann2
Hepatic steatosis (i.e. lipid accumulation) and steatohepatitis have been related to diverse etiologic 
factors, including alcohol, obesity, environmental pollutants. However, no study has so far analyzed 
how these different factors might interplay regarding the progression of liver diseases. The impact 
of the co-exposure to the environmental carcinogen benzo[a]pyrene (B[a]P) and the lifestyle-related 
hepatotoxicant ethanol, was thus tested on in vitro models of steatosis (human HepaRG cell line; 
hybrid human/rat WIF-B9 cell line), and on an in vivo model (obese zebrafish larvae). Steatosis was 
induced prior to chronic treatments (14, 5 or 7 days for HepaRG, WIF-B9 or zebrafish, respectively). 
Toxicity and inflammation were analyzed in all models; the impact of steatosis and ethanol towards 
B[a]P metabolism was studied in HepaRG cells. Cytotoxicity and expression of inflammation markers 
upon co-exposure were increased in all steatotic models, compared to non steatotic counterparts. 
A change of B[a]P metabolism with a decrease in detoxification was detected in HepaRG cells under 
these conditions. A prior steatosis therefore enhanced the toxicity of B[a]P/ethanol co-exposure in vitro 
and in vivo; such a co-exposure might favor the appearance of a steatohepatitis-like state, with the 
development of inflammation. These deleterious effects could be partly explained by B[a]P metabolism 
alterations.
Hepatic steatosis, or fatty liver disease, is a growing epidemic characterized by an accumulation of lipids (mainly 
triglycerides) in hepatocytes. Although steatosis has long been considered as a benign liver disease, this state 
renders the liver more susceptible to further harmful stress, then leading to chronic cell death and inflammation, 
the so-called steatohepatitis1,2. This chronic inflammatory state forms the fertile ground for more severe liver 
diseases, namely fibrosis, cirrhosis and cancer3,4. When unrelated to alcohol, both steatosis and steatohepatitis 
are generally gathered under the term NAFLD for nonalcoholic fatty liver disease, with steatohepatitis termed 
as NASH for nonalcoholic steatohepatitis1,2. NAFLD currently affects around 30% of worldwide general popu-
lation, and is considered as the most common chronic liver disease in several countries, particularly in high-fat 
diet (HFD)-consuming countries1,2,5,6. As obesity predisposes in most cases to steatosis and due to the increasing 
prevalence of obesity, a further increase in NAFLD is expected in the near future with even more serious con-
sequences in terms of clinics and health costs1,7. NAFLD therefore constitutes a major public concern and thus 
deserves more thorough investigation, notably regarding the factors favoring the pathologic progression of stea-
tosis towards steatohepatitis.
Although fatty liver and steatohepatitis most commonly stem from overnutrition and lack of exercise, other 
causes have been recently put forward, such as environmental factors. Indeed, several environmental toxicants, 
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more recently termed metabolism-disrupting chemicals8, have been reported as perturbing the function of endo-
crine and metabolic organs, including the liver, a key controller of body lipid metabolism9. Although several of 
these chemicals could be obesogen9,10, not all would lead to an increase in body fat mass and insulin resistance. 
This is in this context that the terms of toxicant-associated fatty liver disease (TAFLD) and toxicant-associated 
steatohepatitis (TASH) have been proposed by Cave’s group, to indicate the spectrum of fatty liver injury in chem-
ically exposed-non obese individuals11–13. Hence, hepatic steatosis and steatohepatitis can be caused by multiple 
etiologic factors, the three most frequent causes therefore being alcohol (alcoholic liver disease or ALD), obesity/
metabolic syndrome, and environmental toxicants (including drugs), as recently reviewed13. These three major 
etiologies appear to exhibit differences as well as common pathways in terms of the mechanisms involved in the 
development of steatohepatitis13. In this context, how they could interplay remains an underexplored field, despite 
the fact that some reports indicate worsening of steatohepatitis when present in binary combination (alcohol and 
obesity14,15; environmental contaminants and obesity9,16; drugs and obesity17).
Therefore, the present study aimed at evaluating how these three different factors might interplay with respect 
to the progression of liver diseases. To do so, we decided to test the impact of the co-exposure to both the environ-
mental carcinogen benzo[a]pyrene (B[a]P) and the lifestyle-related hepatotoxicant ethanol, following prior estab-
lishment of hepatic steatosis induced by either fatty acid (FA) supplementation (in vitro) or high fat diet (HFD; in 
vivo). The polycyclic aromatic hydrocarbon B[a]P is present in cigarette smoke, diesel exhaust particles as well as 
smoked and grilled food among others. In non-smokers, exposure occurs mainly via diet18. This well-recognized 
genotoxic carcinogen to humans is thus metabolized by the liver (see eg.19), and has been suggested to induce liver 
steatosis20,21 as well as hepatocellular carcinoma (HCC), especially in human22,23. Besides, epidemiological studies 
suggest a synergistic effect of B[a]P and alcohol on HCC risk24. Moreover, we recently evidenced a cooperative 
interaction of B[a]P and ethanol towards cell death in rat primary hepatocytes25. In this context, we decided to 
work on several biological models of hepatic steatosis in order to get strong support regarding our findings. First, 
we used the human HepaRG cell line since this is physiologically one of the closest cell lines to primary human 
hepatocyte26. Secondly, the hybrid human/rat WIF-B9 cell line was chosen due to its high level of differentiation 
into hepatocyte and its sensitivity to low concentrations of chemicals, notably alcohol27,28, compared to HepaRG 
cells; such a feature appears to be interesting when studying concentrations of chemicals relevant to human expo-
sure. Finally, we focused our study on the zebrafish larva model to test in vivo our hypothesis; indeed this model 
is now well recognized as sharing pathophysiological processes with human, especially concerning liver diseases, 
with advantages of time and cost-efficiency in comparison to mammal or rodent models29–31.
The present study showed for the first time that the presence of a prior steatosis enhanced the toxicity of 
B[a]P/ethanol co-exposure both in vitro and in vivo, and that such a co-exposure, even at sub-toxic concentra-
tions, might favor the appearance of a steatohepatitis-like state with an increased expression of several inflamma-
tion markers. Alterations in xenobiotic metabolism may explain, at least in part, some of these deleterious effects.
Methods
In vitro and in vivo models of liver steatosis. For both cell line models, phases of steatosis induction 
and B[a]P/ethanol treatments were determined to be an optimal compromise between a proper differentiated 
hepatocyte state and a maximum duration of treatment that cells could undergo. Protocols of exposure for all 
models are given in Fig. S1.
HepaRG cell culture and treatments. HepaRG cells were cultured according to the standard protocol previously 
described32. After 2 weeks, cell differentiation was induced with 2% DMSO for 2 additional weeks. Differentiated 
cells were then treated during 16 days with or without a mixture of fatty acids (150 µM stearic acid and 150 µM 
oleic acid; see supplementary Methods for commercial source, and Fig. S1 for exposure protocol) in a medium 
containing 5% FBS and 1% DMSO. Our protocol of steatosis induction was adapted from a previous study carried 
out in HepaRG cells, for which both fatty acids were used for a 1-week period33. After 2 days from the onset of 
the experiments, steatotic and non-steatotic cells were treated with or without B[a]P and/or ethanol every 2 or 3 
days. For cytotoxicity studies, B[a]P concentrations ranged from 0.01 to 50 µM, and ethanol concentrations were 
set to 25 and 50 mM. For all further experiments, the selected concentrations were 1 and 2.5 µM for B[a]P and 
25 mM for ethanol.
WIF-B9 cell culture and treatments. WIF-B9 is a hybrid cell line obtained by fusion of Fao rat hepatoma cells 
and WI-38 human fibroblasts34. The WIF-B9 cells were a generous gift from Dr Doris Cassio (UMR Inserm 
S757, Université Paris-Sud, Orsay, France). Cells were cultured in F-12 Ham medium with Coon’s modifica-
tion containing 5% FCS, 0.22 g/L sodium bicarbonate, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 μg/
mL amphotericin B, 2 mM glutamine, and supplemented with HAT (10 μM hypoxanthine, 40 nM aminopterin, 
1.6 μM thymidine). WIF-B9 cells were seeded at 12.5 × 103 cells/cm2; cells were cultured for 7 days until obtaining 
∼80% of confluence, before treatment.
The FA-albumin complex containing medium was prepared by FA saponification with a NaOH/ethanol solu-
tion at 70 °C for 30 min. After ethanol evaporation under nitrogen, FA salts were solubilized in culture medium 
supplemented with 90 µM FA-free bovine serum albumin. The FA/albumin molar ratio was 6.1:1. Steatosis was 
induced by a two days treatment with a medium containing the FA/albumin complex composed of 450 µM oleic 
acid and 100 µM palmitic acid. Steatotic and non-steatotic cells were then exposed or not for an overall 5 days 
period to the toxicants (10 nM B[a]P with or without 5 mM ethanol; see Fig. S1 for exposure protocol). Media and 
treatments with toxicants were renewed on day 3 and kept until end of experiment. Regarding the time of xeno-
biotic exposure for these cells, the choice of 5 days was based on previous data showing that for longer treatments 
of non-steatotic cells with B[a]P, there might be a compensatory proliferation (unpublished data).
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Zebrafish larvae handling and exposures. Animals were handled, treated and killed in agreement with the 
European Union regulations concerning the use and protection of experimental animals (Directive 2010/63/EU). 
All protocols were approved by local ethic committee CREEA (Comité Rennais d’Ethique en matière d’Expéri-
mentation Animale). Zebrafish fertilized embryos, collected following natural spawning, were obtained from the 
Structure Fédérative de Recherche Biosit (INRA LPGP, Rennes, France). Embryos and larvae were raised at 28 °C 
according to standard procedures. Zebrafish larvae (sex unknown) were maintained as previously described35. 
From 4 days post-fertilization (dpf) until last day of treatment renewal (at  9 dpf), larvae were fed daily during 
1 hour before medium renewal with a standard diet (SD, 10% of fat, Tetramin®) or with a high fat diet (HFD) 
made of chicken egg yolk (53% of fat, Sigma-Aldrich). These diets were chosen in accordance with other publica-
tions particularly concerning the lack of standardized diet for zebrafish36,37. At 5 dpf, zebrafish larvae were treated 
by 43 mM ethanol directly added to the incubation medium and/or by 25 nM B[a]P in DMSO (DMSO final pro-
portion: 0.001% v/v), or by this vehicle only (see Fig. S1 for exposure protocol).
Evaluation of steatosis. Oil red O staining. WIF-B9 cells: Oil red O staining was performed to visualize 
neutral lipid droplet accumulation. Cells were washed in phosphate buffer saline (PBS), then stained for 10 min 
with a solution of 0.15% oil red O in 60% isopropanol-PBS. Staining was completed by the addition of hematox-
ylin and eosin for 1 min followed by two washes in PBS. Cell pictures were acquired using a Zeiss Axiolab micro-
scope (Carl Zeiss Microscopy GmbH, Jena, Germany).
Zebrafish larvae: At 5 or 12 dpf, larvae were washed in PBS and then fixed in 4% paraformaldehyde in PBS 
at 4 °C for at least 12 h before being stained overnight in a solution of 0.15% oil red O in 60% isopropanol-PBS. 
Then, larvae were washed three times in PBS and mounted in 80% glycerol-PBS. Images of zebrafish larvae were 
acquired with a LEICA binocular loupe (LEICA Microsystems SAS, Nanterre, France) (magnification x40). Liver 
and larvae sizes were determined from these images using Fiji imaging processing software (ImageJ, National 
Institutes of Health, Bethesda, MD).
Triglyceride assays. HepaRG cells: Cellular triglyceride content was measured using a colorimetric kit purchased 
from Biovision (Milpitas, CA), using the manufacturer’s recommendations. The amount of cellular triglycerides 
was normalized to total proteins determined by the bicinchoninic acid (BCA) method.
WIF-B9 cells and zebrafish larvae: For both cell and larvae samples, total lipid extraction was performed 
according to the Folch method. Total lipids were dissolved in 50 µL of ethanol and 6 µL were used for triglyceride 
measurement with the LabAssay™ Triglyceride Kit (Wako Chemicals GmbH, Neuss, Germany), according to 
the manufacturer’s instructions. Briefly, 300 µL of reaction mix were added to each sample for 5 min at 37 °C, and 
absorbance at 600 nm and 700 nm was measured using a Spectrostar Nano microplate reader (BMG Labtech, 
Ortenberg, Germany). Finally, triglyceride concentration was determined after normalization of absorbance (Δ 
absorbance (abs) = abs at 600 nm minus abs 700 nm), and using a standard curve.
Cholesterol and free fatty acid assays in WIF-B9 cells. Total cholesterol and free fatty acids (FFAs) were also 
measured in steatotic and non-steatotic WIF-B9 cells after two days of treatment with the FA mixture or not. 
Cholesterol quantification was performed by the Infinity cholesterol kit (Thermo Fisher Scientific, Cergy Pontoise, 
France), according to the manufacturer’s instructions. Briefly, 200 µL of reaction solution was added to each sam-
ple for 30 minutes at 37 °C, and absorbance at 492 nm was then measured using a Spectrostar Nano microplate 
reader. Regarding FFA quantification, it was performed by the NEFA-HR kit (Wako Chemicals GmbH, Neuss, 
Germany) according to the manufacturer’s instructions. After addition of the reaction solution and incubation at 
37 °C, absorbance at 546 nm and 660 nm was measured using a Spectrostar Nano microplate reader. FFA concen-
tration was determined after normalization (Δ abs = abs at 546 nm minus abs at 660 nm).
In vitro and in vivo toxicity assays. ATP levels and MTT test. ATP levels were measured with the 
CellTiter-Glo® Luminescent Cell Viability assay purchased from Promega (Charbonnières, France), according 
to the manufacturer’s instructions. Luminescence was measured using the POLARstar Omega microplate reader 
(BMG Labtech, Ortenberg, Germany) or the Spectramax Gemini XS microplate spectrofluorometer (Molecular 
Devices, Sunnyvale, CA). For the MTT test, cells were rinsed with PBS and incubated during 1 hour with a MTT 
solution (0.5 mg/mL in a serum-free and DMSO-free medium). After washing, cells were lysed with pure DMSO. 
Absorbance at 540 nm was measured using the POLARstar Omega microplate reader.
Hoechst/sytox green staining. Apoptotic cell death in WIF-B9 cells was assessed by visualization of chromatin 
condensation or fragmentation after nuclear staining. After treatments, cells were stained with 50 μg/mL Hoechst 
33342 and 93.5 nM Sytox green in the dark for 30 min at 37 °C. Cells were then examined by fluorescence micros-
copy using the ZEISS Axio Scope A1 microscope (>300 cells analyzed per condition of treatment).
Histological analysis of liver toxicity in zebrafish larvae. Histological analysis was performed as previously 
described35. Briefly, after treatments, larvae at 12 dpf were washed in PBS and then fixed in 4% paraformaldehyde 
in PBS at 4 °C before being embedded in paraffin. Then, 4 µm-sections were stained with hematoxylin, eosin and 
safran red (HES) and imaged on Nanozoomer NDP (Hamamatsu Photonics K.K., Japan) (magnification x400). 
Histological count of dead/damaged cells was performed from images (1 or 2 sections) of at least 3 larvae per 
condition. Damaged/dead cells were counted as cellular dropouts, ballooning or vacuolated hepatocytes.
Analysis of gene mRNA expression. HepaRG cells. Total RNA was extracted from ∼106 HepaRG 
cells with the Nucleospin® RNA isolation system (Macherey-Nagel, Hoerdt, France), which included a 
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DNase treatment step. RNA was then reverse-transcribed into cDNA using the High-Capacity cDNA Reverse 
Transcriptase kit (Thermo Fisher Scientific, Cergy Pontoise, France). Real-time quantitative PCR (RT-qPCR) 
was performed using the SYBR Green PCR Master Mix on an Applied Biosystems 7900HT Fast Real-Time PCR 
System (Applied Biosystem, Woolston, UK). Expression of the human TATA box binding protein (TBP) was used 
as reference, and the 2−ΔΔCt method was used to express the relative expression of each selected gene. Sequences 
of the tested human primers are provided in Table S1. For the transcriptomic analysis in HepaRG cells, see sup-
plementary Methods.
WIF-B9 cells. Total RNA was extracted from ∼106 WIF-B9 cells with TRIzol® reagent (Invitrogen, Cergy 
Pontoise, France) according to the manufacturer’s protocol. For each RNA sample, one µg of RNA was 
reverse-transcribed into cDNA using the High capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
RT-qPCR was then performed using SYBR Green on the CFX384 Touch™ Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA). Expression of the rat β-actin was used as reference, and the 2−ΔΔCt method was used to 
express the relative expression of each selected gene. Sequences of the rat primers are provided in Table S1.
Zebrafish larvae. For RNA extraction, 10 to 20 larvae were pooled and homogenized in 100 µL PBS and total 
RNA was extracted with TRIzol® reagent according to the manufacturer’s protocol. RNA samples (1 μg) were 
then reverse-transcribed using the High capacity cDNA Reverse Transcription Kit. RT-qPCR (5 ng of cDNA 
per well) was performed using the same protocol as for the WIF-B9 cells. mRNA expression was normalized by 
means of actb2, 18s and gapdh mRNA levels. The 2−ΔΔCt method was used to express the relative expression of 
each selected gene. Sequences of the zebrafish primers are provided in Table S1. For the evaluation of the hepatic 
mRNA expression of C-reactive protein (crp), see supplementary Methods.
Interleukin-6 quantification. The concentrations of interleukin-6 (IL-6) secreted by HepaRG cells in cul-
ture medium were measured using the Duoset ELISA kit (R&D Systems, Abingdon, United Kingdom), according 
to the manufacturer’s instructions. IL-6 concentration in each well was normalized by the amount of total pro-
teins determined by the BCA method.
Cytochrome P450 activity and HPLC analysis in HepaRG cells. Cytochrome P450 (CYP) activity. 
Cytochrome P450 2E1 (CYP2E1) activity was assessed by determining the formation of 6-hydroxychlorzoxazone 
(6-OH-CZX), as recently reported33. Ethoxyresorufin O-deethylase (EROD) activity was used to measure CYP1A1, 
CYP1A2 and CYP1B1 activities38,39 in HepaRG cells after the 14-day exposure with B[a]P and/or EtOH in steatotic 
or non steatotic cells. Resorufin formation was monitored using a POLARstar Omega microplate reader (BMG 
Labtech, Ortenberg, Germany); excitation and emission wavelengths were 520 and 590 nm, respectively. Reaction 
rates were determined under linear conditions and normalized to total protein concentrations.
B[a]P metabolite detection by HPLC. At the end of the 14-day treatments, cells were washed with warm PBS 
and incubated during 15 min in a red phenol-free William’s E medium at 37 °C and 5% of CO2. This step aimed 
at removing all B[a]P metabolites synthesized during the 14-day treatment. Next, the medium was replaced by a 
phenol red-free William’s E medium containing 25 µM B[a]P with or without 5 mM salicylamide, a strong inhib-
itor of phase II xenobiotic metabolism enzymes (XMEs). After 6 hours at 37 °C and 5% of CO2, the medium was 
collected and centrifuged 15 min at 20,000 g at 4 °C, and 50 µL of the supernatant was directly injected into the 
HPLC system. The HPLC analysis was performed with the Agilent 1100TM system equipped with an Accucore 
PFP column (150 mm × 3 mm, particle size 2.6 µm) coupled with a fluorescent detector, as used by others for 
B[a]P metabolite detection40–42. A gradient of 0.1% acetic acid and acetonitrile was used throughout the exper-
iment at a flow rate of 0.650 mL/min. Acetonitrile proportion ranged from 12.5 to 50% for 25 min and from 50 
to 90% for 1.5 min. The wavelengths used to detect B[a]P metabolites, including B[a]P trans-7,8-dihydrodiol 
and 3-OH-B[a]P-glucuronide, were 365 and 405 nm for excitation and emission, respectively. The peaks of the 
different B[a]P metabolites were identified comparing the spectra of the cells incubated with and without B[a]P. 
Metabolite levels were semi-quantified using the area of each peak compared to the control condition, and were 
normalized by the amount of proteins. The results were expressed as percentage of control values. The peaks of 
B[a]P trans-7,8-dihydrodiol and 3-OH-B[a]P-glucuronide were identified using the respective standards pur-
chased from Toronto Chemicals Research (North York, Canada).
Statistical analysis. All values were presented as means ± SEM (standard error of mean) from at least three 
independent experiments. Multiple comparisons among groups were performed using two-way analysis of vari-
ance (ANOVA) followed by a Bonferroni post-test, or one-way ANOVA followed by a Newman-Keuls post-test. 
To evaluate effects of HFD diet, one-tailed Student t-tests were performed. All statistical analyses were performed 
using GraphPad Prism5 software (GraphPad Software, San Diego, CA, USA). Differences were considered sig-
nificant when P < 0.05. For cytotoxicity assay, 10% effective concentration (EC10) values were determined using 
GraphPad Prism software (GraphPad Software, LaJolla, CA).
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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Results
Prior steatosis increases the long-term toxicity of B[a]P/ethanol co-exposure in the human 
hepatoma HepaRG cell line. Recently, by using the metabolically competent human hepatoma HepaRG 
cell line, we have set up an in vitro human cell model of NAFLD for studying the toxicity of diverse drugs33. 
In order to evaluate the long-term effects of lifestyle-related toxicants, we therefore decided to use this model, 
especially as it is appropriate for such exposure times. First, this cell model was improved to further mimic the in 
vivo situation, notably by using a mixture of two FAs and by extending the duration of FA treatment to 16 days. 
Under these conditions, a lipid overload in cells was detected by microscopy as soon as 2 days of FA treatment, 
with a time-dependency as emphasized by an increase in the size and number of lipid droplets following 16 days 
of FA treatment (Fig. 1a). Lipid accumulation was further validated when measuring the triglyceride cell content, 
with a ∼6-fold increase in the presence of FAs as compared to control (Fig. 1b). A significant increase in APOA4 
mRNA expression was also observed in steatotic cells (Fig. 1c), as recently reported in the context of NAFLD33,43. 
Moreover, CYP2E1 activity was significantly enhanced by 50% in steatotic cells (data not shown), in keeping with 
several investigations performed in patients with NAFLD44–46.
The next set of experiments was carried out in order to determine the dose-response cytotoxicity curve 
of B[a]P, used alone or in combination with ethanol (25 or 50 mM), after a 14 day-treatment in steatotic and 
non-steatotic HepaRG cells. In non-steatotic cells, B[a]P toxicity, as evaluated by MTT test, remained unchanged 
by ethanol, whatever the concentration used (Fig. 1d). In steatotic cells, a marked leftward shift of the curve, that 
is a higher B[a]P cytotoxicity, was observed, with a further shift in presence of ethanol. This was clearly evidenced 
when calculating the EC10 for B[a]P cytotoxicity (Fig. 1e). Indeed, whereas no change in B[a]P EC10 was detected 
in control cells whatever the concentration of ethanol, a significant decrease in this EC10 was observed in steatotic 
cells (4.68 ± 0.95 versus 9.12 ± 2.24 µM in non-steatotic cells), which was further reduced by ethanol (3.12 ± 1.14 
and 2.41 ± 0.84 µM for 25 and 50 mM ethanol, respectively). Similar results were obtained when measuring ATP 
concentration, with a significant difference already reached for 25 mM ethanol (3.07 ± 0.39 versus 4.83 ± 0.91 µM 
without ethanol; Fig. 1f,g). Altogether, these results clearly showed that a prior steatosis enhanced B[a]P cytotox-
icity with an exacerbation of this effect in presence of ethanol. Based upon these results, subsequent investigations 
in HepaRG cells were carried out with 2.5 µM for B[a]P and 25 mM for ethanol. Notably, the high concentrations 
of B[a]P and ethanol used in differentiated HepaRG cells might be explained, at least in part, by high phase II and 
III XME activities47–49.
Prior steatosis increases the toxicity of co-exposure to B[a]P/ethanol used at low concentra-
tions in WIF-B9 cell line. In order to test if a sensitizing effect of steatosis could also be observed at concen-
trations of toxicants closer to human exposure, the hybrid WIF-B9 hepatic cell line was also used in this study. 
Indeed this cell line, which expresses both rat and human XMEs27, was recently shown by our group as reproduc-
ing the signaling cascade previously demonstrated in ethanol-treated primary rat hepatocytes35,50,51. Besides, it 
was found by McVicker and coworkers that co-exposing a parent cell line (WIF-B) to both ethanol and oleic acid 
markedly increased apoptosis when compared to ethanol alone28. Furthermore, it was shown that rat CYP1A1 
and 1A2 were the most inducible CYPs (up to 100-fold with β-naphthoflavone) in WIF-B9 cells27. Finally, we pre-
viously found an increase in CYP2E1 activity upon ethanol treatment in control cells (unpublished data). Hence, 
all these data indicate that the WIF-B9 cell line is suitable to study ethanol and B[a]P metabolism and cytotoxicity.
A first set of experiments was thus performed in order to validate our FA overload protocol in WIF-B9 cells. 
Data from Fig. 2a–c showed that a 2 days exposure with a mixture of FAs increased the number of lipid droplets 
(a), and the triglyceride (b) and cholesterol (c) cellular contents. In contrast, no change was observed regard-
ing the FFA content (Fig. 2d), in line with the very low toxicity detected under control conditions (Fig. 2f,g). 
Interestingly, the mRNA expression of fibroblast growth factor 21 (Fgf21), a known marker of NAFLD52, was 
markedly increased in steatotic WIF-B9 cells (Fig. 2e). All these data firmly validated our in vitro steatosis model.
Prior to testing the effects of B[a]P/ethanol co-exposure in steatotic WIF-B9 cells, experiments were per-
formed in order to set the sub-toxic concentration of each toxicant used for subsequent investigations. Following 
a MTT test carried out after 5 days of treatment (Fig. S2), the selected concentrations were 10 nM and 5 mM, 
for B[a]P and ethanol, respectively, which is close to human exposure; indeed, up to 6.2 nM of B[a]P has been 
detected in sera of smoking women53; regarding alcohol, 5 mM [i.e. 0.23 g/l] is within the drinking guidelines for 
general populations published in 2017 by the International Alliance for Responsible Drinking [http://www.iard.
org/policy-tables/drinking-guidelines-general-population/]). Cell toxicity was then evaluated by counting apop-
totic cells (Fig. 2f) and measuring intracellular ATP content (Fig. 2g). Whereas the toxicity of chemicals alone or 
in co-exposure was low (albeit significant) after a 5 days exposure in non-steatotic WIF-B9 cells, the percentage 
of apoptotic cells markedly increased in steatotic cells (Fig. 2f). This was paralleled by a significant decrease in 
ATP content, especially in steatotic cells (Fig. 2g). It is worth noting that the toxicity of B[a]P/ethanol co-exposure 
was significantly higher than that of each toxicant alone. Altogether, these results showed that prior steatosis 
sensitized WIF-B9 hepatocytes to the toxicity of very low, sub-toxic concentrations of B[a]P and ethanol, with a 
stronger effect of co-exposure.
Obese larvae exhibit high hepatotoxicity towards B[a]P/ethanol co-exposure. In order to test 
whether steatosis could also enhance in vivo the hepatotoxicity of B[a]P/ethanol co-exposure, zebrafish larvae fed 
with a HFD (HFD larvae) were used as a suitable model for obesity-related NAFLD54,55. It is also noteworthy that 
ethanol can induce liver steatosis in zebrafish larvae56,57. We first showed that our feeding conditions did induce 
liver steatosis. Indeed, as shown in Fig. 3, a one-day HFD not only increased the oil red-O staining in liver (a) but 
also the size of liver relatively to whole body (b), when compared to standard diet (SD). Regarding a potential 
interference with adipose tissue on the oil red-O staining at 5 dpf, it could be easily discarded as adipose tissue in 
larvae is known to appear only from 8 dpf 58,59. The triglyceride content of whole larvae was also found to increase 
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Figure 1. Toxicity of B[a]P in differentiated HepaRG cells is favored by steatosis and ethanol co-exposure. 
(a) Phase contrast microscopy of non-steatotic cells (−FA) and steatotic cells (+FA) after 2 and 16 days of 
incubation with a mixture of stearic acid and oleic acid. (b) Cellular triglyceride content in non-steatotic (−FA) 
and steatotic (+FA) cells after 16 days of FA overload. (c) mRNA levels of APOA4 in non-steatotic (−FA) and 
steatotic (+FA) cells after 16 days of FA overload. (d) Cell viability determined by the MTT test in non-steatotic 
(−FA) and steatotic (+FA) cells exposed for 14 days to 0, 25 and 50 mM ethanol and a large range of B[a]P 
concentrations. (e) Corresponding B[a]P EC10 values in non-steatotic (-FA) and steatotic (+FA) cells exposed 
to 0, 25 and 50 mM ethanol. (f,g) Cell viability assessed by cellular ATP levels and corresponding B[a]P EC10 in 
non-steatotic (−FA) and steatotic (+FA) cells exposed for 14 days to 0, 25 and 50 mM ethanol and a large range 
of B[a]P concentrations. Results are means ± SEM for at least three independent cultures. (b,c) #Significantly 
different from non-steatotic (−FA) cells. (e,g) #Significantly different from non-steatotic cells; *Significantly 
different from non-steatotic HepaRG cells treated by the same concentration of ethanol; aSignificantly different 
from steatotic HepaRG cells not treated by ethanol.
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Figure 2. Toxicity of B[a]P in differentiated WIF-B9 cells is favored by steatosis and ethanol co-exposure. 
(a–e) Prior steatosis was induced by a 2 days incubation with palmitic acid and oleic acid (+FA conditions). 
(a) Fluorescence microscopy analysis of neutral lipid droplets after oil red O staining in non-steatotic (−FA) 
and steatotic (+FA) cells. Cellular triglyceride (b), cholesterol (c) and FFA (d) contents in non-steatotic (−FA) 
and steatotic (+FA). (e) mRNA levels of Fgf21 in non-steatotic (−FA) and steatotic (+FA) cells. (f,g) Non-
steatotic (−FA) and steatotic (+FA) cells were untreated (C) or treated with 10 nM B[a]P (B), 5 mM ethanol 
(E) or a combination of both toxicants (BE) for 5 days prior to evaluation of cytotoxicity by (f) counting 
apoptotic cells or (g) analyzing ATP content. Results are means ± SEM for at least three independent cultures. 
(b,c,e) #Significantly different from non-steatotic cells. (f,g) #Significantly different from non-steatotic cells; 
*Significantly different from untreated non-steatotic or steatotic cells; aSignificantly different from non-steatotic 
or steatotic cells treated by ethanol only; bSignificantly different from non-steatotic or steatotic cells treated by 
B[a]P only.
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upon HFD from one day of HFD (5dpf), with a marked effect observed after 8 days of diet (12 dpf) (Fig. 3c). The 
mRNA levels of apoa2 and cyp2y3 (homologous to the human CYP2E1 gene), two genes whose expression is 
modulated during NAFLD46,60, were enhanced in whole HFD larvae (Fig. 3d).
For subsequent investigations, 25 nM B[a]P and 43 mM ethanol (corresponding to 10 mM ethanol inside lar-
vae; data not shown) were chosen as these concentrations induced a very low mortality within the SD larvae 
population following 7 days of treatment (Fig. S3). In order to evaluate hepatotoxicity, a histological analysis 
Figure 3. Induction of steatosis in zebrafish larvae under high-fat diet and exacerbation of liver damage 
severity upon co-exposure in larvae with steatosis. Zebrafish larvae were fed with a standard diet (SD) or a high-
fat diet (HFD) from 4 dpf until 5 dpf (a–d) or until 12 dpf (c–f). Lipid accumulation (a) was analyzed after oil 
red O staining in HFD larvae as well as in SD larvae. White dotted line in the right-hand side panels outlines 
liver in the 2x-magnifications. (b) From images acquired in (a), the ratio of liver sizes to whole larva sizes was 
determined on 5 dpf zebrafish larvae. Images are representative of at least 3 larvae. Triglyceride content (c) as 
well as mRNA levels of apoa2 and cyp2y3 (d) were determined in SD and HFD larvae. In (d), data are expressed 
relative to mRNA level found in SD larvae, arbitrarily set at 1 unit for each time (5 and 12 dpf). (e,f) From 5 
dpf, SD and HFD zebrafish were either left untreated (C), or treated with 25 nM B[a]P (B), 43 mM ethanol (E) 
or a combination of both toxicants (BE) for 7 days. (e) Liver damages were evaluated on zebrafish liver section 
after HES staining (magnification x400). Black dotted line outlines liver. Damaged/dead cells were indicated 
by red arrows for hepatocyte dropouts, and by black arrows for ballooned or vacuolated hepatocytes. Images 
are representative of at least 3 larvae. Values are the mean ± SEM of at least three independent experiments or 
larvae. (f) From images obtained in (e), histological count of damaged cells was realized. (b–d) #Significantly 
different from SD larvae. (f) #Significantly different from SD larvae; *Significantly different from untreated SD or 
HFD larvae; aSignificantly different from larvae treated by ethanol only; bSignificantly different from SD or HFD 
larvae treated by B[a]P only.
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was performed. HFD markedly increased liver alterations upon B[a]P/ethanol co-exposure when compared to 
SD, with an increase in the number of damaged/dead cells (Fig. 3e). This was clearly visualized on the histo-
gram plotting the number of damaged/dead cells counted under the different experimental conditions (Fig. 3f). 
Importantly, toxicity of B[a]P/ethanol co-exposure was significantly higher compared to each chemical alone. 
Therefore, the in vivo steatosis also sensitizes liver to B[a]P/ethanol-related toxicity.
B[a]P/ethanol co-exposure triggers inflammation in NAFLD both in vitro and in vivo. The next 
set of experiments was performed in order to test whether the increased toxicity of B[a]P/ethanol co-exposure 
was paralleled by the onset of an inflammatory state. First, the expression of several pro-inflammatory cytokines 
was analyzed in both in vitro cell models. In HepaRG cells treated or not with B[a]P (2.5 µM) and/or ethanol 
(25 mM) for 14 days, a significant increase in interleukin 6 (IL6) and interleukin 1β (IL1β) mRNA expression 
was observed in steatotic cells as compared to non-steatotic cells (Fig. 4a,c). However, no significant effect of 
toxicants, used alone or in co-exposure, was detected in steatotic cells. Nevertheless, secreted IL6 levels were 
enhanced, especially upon B[a]P/ethanol co-exposure, with a stronger effect detected in steatotic HepaRG cells 
(Fig. 4b). Regarding the IL1β pathway, a significant increase in mRNA expression of the IL1β receptor IL1R1 was 
also detected especially upon toxicant co-exposure in steatotic cells (Fig. 4d).
In WIF-B9 cells treated or not by B[a]P (10 nM) and/or ethanol (5 mM) for 5 days, a significant increase 
in tumor necrosis factor α (Tnfα) mRNA expression was found (by ∼2.8-fold) upon toxicant co-exposure in 
steatotic cells (Fig. 4e). Such an onset of inflammation in steatotic WIF-B9 cells was confirmed by analyzing 
the mRNA expression of Crp (Fig. 4f), a well-known marker of inflammation61. Indeed, Crp mRNA expression 
was higher not only in presence of steatosis, but was further increased when steatotic cells were co-treated with 
B[a]P/ethanol.
Regarding the in vivo model, the co-exposure of zebrafish larvae to B[a]P (25 nM)/ethanol (43 mM) for 7 days 
resulted in a significant increase in crp, tnfa and il1b mRNA expression in whole animals but only under HFD 
conditions (Fig. 5a–c), thus corroborating the effects observed in vitro. Note that crp mRNA expression was sig-
nificantly higher in HFD larvae compared to SD larvae in the absence of any treatment (Fig. 5a). In line with the 
results obtained from whole larvae, hepatic crp mRNA expression in HFD larvae was higher with B[a]P/ethanol 
co-exposure compared to each toxicant alone (Fig. S4).
Effects of steatosis and ethanol co-exposure on phase I and II XMEs in HepaRG cells. In order 
to get insight into the possible mechanisms involved in the sensitizing effects of steatosis and ethanol co-exposure 
towards B[a]P toxicity, we performed a series of investigations in HepaRG cells to determine whether lipid 
overload and ethanol could impair the expression of the main XMEs involved in B[a]P metabolism, especially 
CYP1A1, 1A2 and 1B1. As expected, the mRNA expression of these CYPs was markedly enhanced after 14 days 
of treatment with 2.5 µM B[a]P in steatotic and non-steatotic HepaRG cells, with the strongest effect observed 
for CYP1A1 (Fig. 6a–c). Of note, increased CYP1A2 mRNA expression was lesser in the presence of steatosis 
(Fig. 6b). Moreover, mRNA expression of CYP1A1, 1A2 and 1B1 was significantly decreased by 25 mM ethanol 
co-exposure both in steatotic and non-steatotic cells (Fig. 6a–c). Next, EROD activity was assessed in order to 
evaluate the overall activity of these CYPs. EROD activity was markedly increased by B[a]P but no difference was 
observed between steatotic and non-steatotic HepaRG cells (Fig. 6d). However, ethanol co-exposure resulted in 
a lesser increase of EROD activity (with similar effects when comparing steatotic and non-steatotic cells), thus 
reflecting the mRNA expression profile of CYP1A1 and 1B1. Therefore, it appears that the activation of the CYP1 
pathway by B[a]P alone or with ethanol was not affected by prior steatosis in HepaRG cells.
We also took advantage of a whole-genome transcriptome analysis (GSE102536 – see supplementary Methods 
for protocol) to determine whether steatosis and ethanol altered the expression of other XMEs involved or not in 
B[a]P biotransformation (Table S2). Notably, this analysis confirmed our results regarding the mRNA expression 
of CYP1A1, 1A2 and 1B1, especially the lower expression of CYP1A2 in steatotic HepaRG cells treated or not 
with B[a]P and ethanol. Furthermore, the transcriptome analysis clearly showed that lipid overload repressed the 
expression of other phase I XMEs involved in B[a]P metabolism such as CYP3A4, CYP2C19, aldo-keto reduc-
tases (AKRs) and epoxide hydrolases (EPHXs)19,62. Steatosis also induced a downregulation of several phase II 
XMEs involved in B[a]P detoxification including glutathione-S-transferases (GSTs), sulfotransferases (SULTs) 
and UDP-glucuronosyl transferases (UGTs), as well as a downregulation of XMEs involved in ethanol metabo-
lism such as alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs). The mRNA expression of 
CYP2E1 was however increased in steatotic HepaRG cells in the absence of any treatment. It was also noteworthy 
that, among the 12 experimental conditions tested, the lowest mRNA expression of phase I and phase II XMEs 
was mostly observed in steatotic HepaRG cells treated with 2.5 µM B[a]P. Moreover, the lowest expression of 
several phase II XMEs such as GSTM2P1, GSTA7P, SULT1B1, SULT1C2, UGT2B7 and UGT2A3 was observed 
in steatotic HepaRG cells co-exposed to 2.5 µM B[a]P and 25 mM ethanol (Table S2).
Effects of steatosis and ethanol co-exposure on the amount of B[a]P metabolites produced in 
HepaRG cells. Based upon the above results, it appeared that the whole B[a]P metabolism might be altered in 
steatotic HepaRG cells exposed to ethanol. Hence, at the end of the 14-day exposure and after a 15-min washout, 
we assessed the formation of B[a]P metabolites after an acute incubation of cells with 25 µM B[a]P. Importantly, 
this analysis was performed not only in steatotic and non-steatotic HepaRG cells treated for 14 days with 2.5 µM 
B[a]P with or without ethanol but also in cells not previously exposed to this toxicant. Thus, the ability of HepaRG 
cells to metabolize B[a]P was determined even in cells that have not been chronically exposed to B[a]P.
Examples of three representative HPLC chromatograms are shown in Fig. 7a, corresponding to non-steatotic 
cells exposed to B[a]P, non-steatotic cells co-exposed to B[a]P/ethanol, and steatotic cells co-exposed to 
B[a]P/ethanol. Several peaks could be identified on these HPLC chromatograms, with a clear reduction of the 
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overall amount of B[a]P metabolites by ethanol co-exposure and a further decrease in the presence of steatosis 
(Fig. 7a). Notably, steatosis-induced reduction of all detected B[a]P metabolites was observed under the different 
experimental conditions when the amount of B[a]P metabolites was assessed using the areas under the curve 
(AUC) (Fig. 7b).
In order to get further information regarding the nature of the detected B[a]P metabolites, we next performed 
investigations in HepaRG cells acutely exposed to 25 µM B[a]P and 5 mM salicylamide, a known inhibitor of 
Figure 4. B[a]P/ethanol co-exposure favors a pro-inflammatory state in steatotic HepaRG and WIF-B9 cells. 
(a–d) Non-steatotic (−FA) and steatotic (+FA) HepaRG cells were untreated (C) or treated with 2.5 µM B[a]P 
(B), 25 mM ethanol (E) or a combination of both toxicants (BE). (e,f) Non-steatotic (−FA) and steatotic (+FA) 
WIF-B9 cells were untreated (C) or treated with 10 nM B[a]P (B), 5 mM ethanol (E) or a combination of both 
toxicants (BE). (a,c,d) mRNA expression of IL-6, IL1B and IL1R1. (b) Secreted IL6 levels in the culture medium. 
(e,f) mRNA expression of Tnfα and Crp. Results are means ± SEM for at least three independent cultures. 
#Significantly different from non-steatotic cells; *Significantly different from untreated non-steatotic or steatotic 
cells; aSignificantly different from non-steatotic or steatotic cells treated by ethanol only; bSignificantly different 
from non-steatotic or steatotic cells treated by B[a]P only.
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phase II enzymes. Interestingly, most of the peaks were reduced by salicylamide (Fig. 8a), thus indicating that they 
corresponded to metabolites produced by phase II XMEs. We also identified two important B[a]P metabolites, 
namely 3-OH-B[a]P-glucuronide and B[a]P trans-7,8-dihydrodiol (Fig. S5), using the corresponding standards 
(respectively metabolites 2 and 1 on the chromatograms in Fig. 8A). Notably, salicylamide treatment reduced the 
peak corresponding to 3-OH-B[a]P-glucuronide and concomitantly increased the peak corresponding to B[a]P 
trans-7,8-dihydrodiol (Fig. S6), a precursor of several toxic B[a]P metabolites (Fig. S5).
The amounts of B[a]P trans-7,8-dihydrodiol and 3-OH-B[a]P-glucuronide were next assessed. Whereas 
no significant difference in the amount of B[a]P trans-7,8-dihydrodiol could be observed between steatotic 
and non-steatotic HepaRG cells (Fig. 8b), that of 3-OH-B[a]P-glucuronide was significantly reduced in the 
Figure 5. B[a]P/ethanol co-exposure favors a pro-inflammatory state in in HFD zebrafish larvae. Zebrafish larvae 
were fed with a standard diet (SD) or a high fat diet (HFD) and were either left untreated (C), or treated with 25 nM 
B[a]P (B), 43 mM ethanol (E) or a combination of both toxicants (BE) for 7 days. (a–c) mRNA expression of crp, 
tnfa and il1b, respectively. Data are expressed relative to mRNA level found in control SD larvae, arbitrarily set at 
1 unit. Values are the mean ± SEM of at least twelve independent experiments. #Significantly different from SD 
larvae; *Significantly different from untreated SD or HFD larvae; aSignificantly different from larvae treated by 
ethanol only; bSignificantly different from SD or HFD larvae treated by B[a]P only.
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presence of steatosis (Fig. 8c). It was worth noting that a significant decrease in the amount of both metabolites 
was detected in steatotic HepaRG cells co-exposed to B[a]P/ethanol as compared to steatotic cells treated with 
B[a]P alone (Fig. 8b,c). Interestingly, the ratio of B[a]P trans-7,8-dihydrodiol level to the amount of all metabo-
lites was found markedly enhanced in steatotic HepaRG cells co-exposed to B[a]P/ethanol (Fig. 8d). Altogether, 
these results suggested that steatosis and ethanol co-exposure could induce a shift in B[a]P metabolism with an 
impairment of its detoxification.
Discussion
Hepatic steatosis and steatohepatitis have been related to diverse etiologic factors, the most frequent being alcohol 
(ALD), obesity (NAFLD), and environmental toxicants (TASH)9,13. However, to our knowledge, no study has 
been performed so far with the aim of analyzing how these three different factors might interplay with respect 
to the progression of liver diseases. In this context, we decided to test the impact of the co-exposure to both the 
environmental carcinogen B[a]P and the lifestyle-related hepatotoxicant ethanol, on different models of hepatic 
steatosis induced by either FA overload (in vitro) or HFD (in vivo). The present study shows for the first time that 
the presence of a prior steatosis significantly enhanced the toxicity of B[a]P/ethanol co-exposure, and that such 
a co-exposure might favor the appearance of a steatohepatitis-like state, even at concentrations determined as 
sub-toxic under FA-free conditions.
Using two different in vitro models of steatosis, a significant increase in cell death (notably associated with a 
decrease in intracellular ATP content) was detected upon co-exposure to both toxicants. This cytotoxicity was 
associated with an increase in the mRNA expression of some cytokines (IL1β and its receptor IL1R1, in HepaRG 
cells; Tnfα in WIF-B9 cells), as well as in Crp mRNA expression in these latter cells. Secreted IL6 was also detected 
in HepaRG cells. This therefore might indicate the onset of inflammation. The differences observed with regard 
to the type of altered cytokines between HepaRG and WIF-B9 cells might stem from either the concentrations 
of toxicants (B[a]P/ethanol: 2.5 µM/25 mM for HepaRG cells versus 10 nM/5 mM for WIF-B9 cells), the time 
Figure 6. mRNA expression of CYP1A1, CYP1A2 and CYP1B1 and EROD activity are disturbed in non-
steatotic and steatotic HepaRG cells treated with B[a]P and ethanol. Non-steatotic (−FA) and steatotic (+FA) 
HepaRG cells were untreated (C) or treated with 2.5 µM B[a]P (B), 25 mM ethanol (E) or a combination of 
both toxicants (BE). (a–c) mRNA expression of CYP1A1, CYP1A2 and CYP1B1. (d) EROD activity. Results 
are means ± SEM for at least three independent cultures. #Significantly different from non-steatotic cells; 
*Significantly different from untreated non-steatotic or steatotic cells; aSignificantly different from non-steatotic 
or steatotic cells treated by ethanol only; bSignificantly different from non-steatotic or steatotic cells treated by 
B[a]P only.
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of co-exposure (14 days for HepaRG cells versus 5 days for WIF-B9 cells), or interspecies features (human for 
HepaRG cells versus hybrid human/rat for WIF-B9 cells).
Notably, an increase in cell death as well as in the expression of several markers of inflammation (crp, tnfa, 
il1b), was also found in HFD zebrafish larvae co-exposed to B[a]P and ethanol. Zebrafish larvae possess a func-
tional immune system (as evidenced by neutrophil recruitment63), thus showing that the pathological progression 
of steatosis observed in our two in vitro models could also be seen in an in vivo model of NAFLD which is closer 
to the clinical situation. These observations not only emphasize the utility of the two in vitro models of steatosis 
presently developed, as already reported28,33, but also further reinforce the attractiveness of the zebrafish larvae as 
a suitable model to study xenobiotic-related liver diseases35. Moreover, the fact that the steatohepatitis-like state 
was observed with different FA mixtures (in vitro) and different lipids (in vivo) strengthens the robustness of our 
experimental results and their possible extrapolation to NAFLD patients who are likely to eat different types of 
high-fat diets.
It was previously shown that alcohol intoxication in the context of obesity was able to aggravate NAFLD14,15. 
Similarly, recent data demonstrated that endocrine disruptors, such as bisphenol A or PCB153, could also worsen 
NAFLD when promoted by high fat diet9. In the present study, at the concentrations tested, the effects of ethanol 
or B[a]P alone in steatotic cells were quite minor, if any, especially on inflammation markers. From our data, it 
therefore clearly appears that this is the combination of all three risk factors (obesity, alcohol consumption, expo-
sure to environmental toxicants) that can enhance the risk of fatty liver disease progression. This might give a clue 
Figure 7. B[a]P metabolism is disturbed in HepaRG cells by steatosis and ethanol co-exposure. Non-steatotic 
(−FA) and steatotic (+FA) HepaRG cells were untreated (C) or treated with 2.5 µM B[a]P (B), 25 mM ethanol 
(E) or a combination of both toxicants (BE). At the end of the 14-day toxicant exposure and after a 15-minute 
washout, B[a]P metabolites were analyzed in the culture media after an acute incubation of 25 µM B[a]P.  
(a) Examples of three representative HPLC chromatograms corresponding to non-steatotic cells exposed to 
B[a]P (B), non-steatotic cells co-exposed to B[a]P and ethanol (BE), and steatotic cells co-exposed to B[a]P and 
ethanol (BE + FA). (b) Amount of all detected B[a]P metabolites determined as the sum of their AUCs (areas 
under the curve) and normalized to the total cellular protein content. Results are means ± SEM for at least three 
independent cultures. #Significantly different from non-steatotic cells; *Significantly different from untreated 
non-steatotic cells; aSignificantly different from non-steatotic cells treated by ethanol only; bSignificantly 
different from non-steatotic cells treated by B[a]P only.
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Figure 8. B[a]P metabolism by phase I and II XMEs is disturbed in HepaRG cells by steatosis and ethanol co-
exposure. Non-steatotic (−FA) and steatotic (+FA) HepaRG cells were untreated (C) or treated with 2.5 µM 
B[a]P (B), 25 mM ethanol (E) or a combination of both toxicants (BE). At the end of the 14-day toxicant 
exposure and after a 15-minute washout, B[a]P metabolites were analyzed in the culture media after an acute 
incubation of 25 µM B[a]P with or without 5 mM salicylamide, a strong inhibitor of phase II XMEs.  
(a) Examples of two representative HPLC chromatograms corresponding to non-steatotic cells treated for 14 
days with B[a]P, and then acutely exposed to B[a]P (B) or B[a]P with salicylamide (B + Sali). (b) Amount of 
B[a]P trans-7,8-dihydrodiol (peak 1 on panel a) assessed by its AUC and normalized to the total cellular protein 
content. (c) Amount of 3-OH-B[a]P-glucuronide (peak 2 on panel a) assessed by its AUC and normalized to 
the total cellular protein content. (d) Ratio of the amount of B[a]P trans-7,8-dihydrodiol to the amount of all 
detected metabolites. Results are means ± SEM for at least three independent cultures. #Significantly different 
from non-steatotic cells; *Significantly different from untreated non-steatotic or steatotic cells; aSignificantly 
different from non-steatotic or steatotic cells treated by ethanol only; bSignificantly different from non-steatotic 
or steatotic cells treated by B[a]P only.
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as to why there has been a large increase in the incidence of fatty liver diseases throughout the past two decades, 
accompanied by an increased risk of HCC among patients with NAFLD5.
We previously demonstrated in primary rat hepatocytes that the cooperative interaction between B[a]P and 
ethanol on cell death involved both B[a]P and ethanol metabolism25. Besides, a few studies indicated an impact 
of liver steatosis on xenobiotic metabolism, with possible consequences on drug biotransformation64–69, and toxi-
cokinetics of environmental contaminants70. We therefore decided to focus on xenobiotic metabolism in HepaRG 
cells, especially that related to B[a]P. As expected from previous works64–67, steatosis per se down-regulated the 
expression of several phase I and II XMEs of HepaRG cells, with some exceptions such as CYP2E1, ALDH1A3 
and GSTM2P1 whose expression was increased (Table S2). Such CYP2E1 induction has already been reported in 
clinical and experimental NAFLD33,44,46.
Regarding more specifically B[a]P metabolism, it is worth noting that neither CYP1A1 nor CYP1B1 mRNA 
expressions were affected by steatosis alone, in contrast to CYP1A2 whose expression was reduced. Despite a 
marked induction of these CYPs by B[a]P, ethanol however decreased it in both steatotic and non-steatotic cells. 
One might propose that such an impact of ethanol would be related to its inducing effect on CYP2E1 in HepaRG 
cells. Indeed, it has been previously shown that CYP2E1 overexpression repressed the activity of the CYP1A1 gene 
promoter and vice versa, via a cross-regulation involving reactive oxygen species production between those two 
enzymes71,72. However, when looking at the present transcriptomics data, it appears that like CYP1A1, CYP2E1 
mRNA expression was also down-regulated in cells exposed to B[a]P/ethanol mixture (Table S2), and so was the 
activity of both CYP1A1 (Fig. 6d) and CYP2E1 (data not shown), especially in steatotic cells. Based upon the 
fact that the mRNA expression of several phase I and phase II XMEs was affected in steatotic cells exposed to 
both B[a]P and ethanol (Table S2), pathophysiological parameters such as oxidative stress72,73, inflammation74,75, 
or lipid accumulation68,69, might be involved in these effects, e.g. by controlling the activity or expression of key 
nuclear receptors. With regard to an effect of inflammation, it has been previously reported that CYP1A2 expres-
sion is decreased in the presence of pro-inflammatory cytokines such as TNFα and IL1β, likely through an effect 
on the aryl hydrocarbon receptor (AhR)76. Such a mechanism might be involved in the decrease in CYP1A2 
mRNA expression presently observed in steatotic HepaRG cells since the IL1β pathway was upregulated.
The fact that xenobiotic metabolism was altered by steatosis and toxicant co-exposure led us to analyze the 
B[a]P metabolites produced under our different conditions. From the present results, it was clear that far less 
metabolites were produced by steatotic HepaRG cells following the 14 days treatment with both B[a]P (2.5 µM) 
and ethanol (25 mM) as compared to non-steatotic cells (Fig. 7b). Such a decrease in the overall amount of metab-
olites might result from the reduced expression of the enzymes involved in B[a]P biotransformation, as discussed 
above. As EROD activity did not seem to be affected by steatosis whatever the test conditions, one might then sup-
pose that enzymes other than CYP1 would be targeted. In line with this, our transcriptomic analysis evidenced 
in steatotic cells a reduced expression of several enzymes involved in B[a]P metabolism including CYP3A4 and 
2C19 as well as AKRs, EPHXs, GSTs and UGTs77,78. Moreover, a significant reduction in the amount of 3-OH- 
B[a]P-glucuronide was observed in steatotic cells (Fig. 8c), thus indicating that B[a]P detoxification via the UGT 
pathway would be impaired. Interestingly, previous works showed a decrease in the activity of phase II XMEs as 
NAFLD progresses from steatosis to steatohepatitis79.
It is noteworthy that B[a]P trans-7,8-dihydrodiol is the precursor of (±)-anti-B[a]P-diol-epoxide (BPDE) 
(Figure S4), the major carcinogenic intermediate of B[a]P80. Our results showing an increase in the ratio of 
B[a]P trans-7,8-dihydrodiol/all metabolites in steatotic cells co-exposed to B[a]P/ethanol (Fig. 8d) thus sug-
gested an impairment of B[a]P detoxification. As a consequence, one might then expect higher formation of 
BPDE-DNA adducts and other DNA damages, eventually leading to an increased cell toxicity and higher risk 
of carcinogenesis. In addition to DNA damages, it would also be interesting to analyze the DNA repair systems. 
Indeed, a recent study dealing with the impact of acidic pH on B[a]P metabolism demonstrated a delayed B[a]P 
metabolism associated with a decreased DNA repair activity, ultimately leading to higher DNA damage and DNA 
adduct formation81.
In conclusion, we presently report for the first time that a co-exposure to B[a]P/ethanol favors in vitro and 
in vivo the progression of fatty liver to a more severe stage characterized by cytotoxicity and a pro-inflammatory 
state. This progression seems to be promoted by a profound effect of steatosis and ethanol on the expression on 
phase I and II XMEs leading to a change in the balance between B[a]P bioactivation and detoxification. Based 
upon the fact that NAFLD is a growing public health burden, associated with a significant economic impact1,7, 
elucidation of the mechanisms whereby B[a]P and ethanol co-exposure aggravate NAFLD will have to be thor-
oughly tackled in the near future.
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